Mallinckrodt (NYSE: MNK) reported Q3 EPS of $2.05, $0.23 better than the analyst estimate of $1.82. Revenue for the quarter came in at $965.1 million versus the consensus estimate of $985.3 million.

"Mallinckrodt reported another solid quarter, with meaningful top- and bottom-line growth in our Specialty Brands segment. The revenue contributed by specialty biopharmaceutical products continues to increase as an overall percentage of net sales," said Mark Trudeau, Chief Executive Officer and President of Mallinckrodt. "The recent announcement of the planned divestiture of our contrast media and delivery systems business further demonstrates our commitment to the strategy we have outlined, as we refine our portfolio to further transform the company into a leading specialty biopharmaceutical company focused on long-term, durable and sustained growth."

For earnings history and earnings-related data on Mallinckrodt (MNK) click here.

Earnings Management Comments

Leerink Partners Upgrades Mallinckrodt plc (MNK) to Outperform on ValuationAugust 6, 2015 2:40 PM Piper Jaffray Cuts Price Target on Mallinckrodt (MNK) to $140 Following 3Q EPS Beat August 5, 2015 9:40 AM Mallinckrodt (MNK) PT, Estimates Lowered at Leerink Partners Following Mixed Q3August 5, 2015 7:48 AM JPMorgan Downgrades Mallinckrodt plc (MNK) to NeutralAugust 5, 2015 7:10 AM Mallinckrodt plc Reports Fiscal 2015 Third Quarter Financial ResultsAugust 4, 2015 6:55 AM